Previous Client

Return to Sector or view our Current Clients.

Untitled Document

Rainbow Coral Corp. (RBCC)

Rainbow Coral Corp. (RBCC) is spearheading the most innovative scientific and medical breakthroughs in the $84.6 billion global biotechnology industry, and is focused on bringing new deals to investors by year-end. The company and its joint venture partners continue to market and develop breakthrough innovations, currently focused on 3D printing technology and substance abuse treatment.

RBCC partner, N3D Biosciences, has developed the 3D BIO Assay - the first commercially available 3D bioprinting system designed specifically for quick, high-volume drug screening. Its automated toxicity screening uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than the competing bioprinting technologies currently on the market. Major purchasers of these bioprinters are universities and research institutes, which use them for breakthrough research and production. A new research publication, 3D Bioprinting Market, 2014-2030 by Roots Analysis, lists N3D as a leading stakeholder in an industry forecasted to be worth $10 billion by 2030.

Rainbow Biosciences, LLC, a new division of RBCC, is focused on identifying, developing and marketing the next generation of bioscience solutions for physicians, researchers and pharmaceutical engineers. The company is positioned to leverage proven resources that assess, enhance and realize the commercial potential of bioscience discoveries. RBCC is nearing agreements with a Canadian medical group that utilizes Naltrexone to treat substance abuse and with another company to distribute Naltrexone in Canada.

As RBCC advances its position in the multi-billion dollar global regenerative and precision medicine markets, the company leverages proven resources that assess, enhance and realize the commercial potential of bioscience discoveries to deliver substantial returns to early investors. The company is headed by president and CEO Kimberly Palmer, a healthcare expert in charge of implementing RBCC's developing business strategy in the field of regenerative medicine. Palmer has served as a business consultant to private surgeons, providing administrative and clinical support for a variety of medical practices and, as a registered nurse, also brings extensive experience with surgical pre- and post-operative patient care to RBCC.

Transfer Agent
Island Stock Transfer
15500 Roosevelt Boulevard, Suite 301
Clearwater, FL, 33760

Investor Relations
3370 N. Hayden Rd.
Scottsdale, AZ. 85251

Key Investment Highlights
N3D technology could revolutionize cell research
Company is Spearheading Remarkable Breakthroughs
U.S. Biotech Industry Valued at $84.6 Billion

Industry: Biotechnology
Sector: Healthcare
Sub-industry: Medical Laboratories & Research

Share Information


Additional Resources


The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.